Science and Discovery

Astrazeneca

1 article

FDA advisory panel in a hearing room, with a split decision on AstraZeneca's breast cancer drug, casting uncertainty for patients.
Health & Medicine

FDA advisory panel rejects AstraZeneca breast cancer drug

A U.S. Food and Drug Administration advisory committee voted 3 to 6 against the benefit-risk profile of AstraZeneca's breast cancer drug camizestrant, according to AstraZeneca . This decision creates

Aram Sarkisian·May 22, 2026